Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
! {8 P7 O8 o+ W4 E% Y6 J& V9 UNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 ; V# e# |" N& [
+ Author Affiliations- e/ ^0 O2 H) x3 L4 V- c
5 d" p( J3 f1 {9 F5 D. N1 o1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan . w: D% F& L& i: i* f3 F b* B9 S$ C9 `
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 9 g2 o. ] l5 {9 Q' L C
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
7 B% e6 h; R) E) o2 ~4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
4 e0 b5 t3 V5 a: ]5 Q5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 2 l5 Q0 ~6 n* h# {+ E
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
! G1 m# P9 n* t) {' c9 y7Kinki University School of Medicine, Osaka 589-8511, Japan 2 _. e: }# J* ?( {9 w
8Izumi Municipal Hospital, Osaka 594-0071, Japan
5 T5 a. D$ t) U& {: h! M1 a6 q# k9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan 2 u" M4 }, [' O$ W* H
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
, }/ _( \2 g% B0 t+ gAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 5 s! o" a5 z* }. Z
" w6 ~, f. v" v, J) A0 f i
|